CytomX Therapeutics (CytomX Therapeutics) GF Value Rank : 4 (As of Apr. 30, 2024)

View and export this data going back to 2015. Start your Free Trial

What is CytomX Therapeutics GF Value Rank?

CytomX Therapeutics has the GF Value Rank of 4.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of CytomX Therapeutics's GF Value Rank

For the Biotechnology subindustry, CytomX Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's GF Value Rank falls into.

CytomX Therapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (CytomX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (NAS:CTMX) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Executives

Marcia Belvin	officer: SVP, Chief Scientific Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Christopher Ogden	officer: SVP, Finance and Accounting	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Jeffrey B Landau	officer: Chief Financial Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lloyd A Rowland	officer: General Counsel	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Sean A. Mccarthy	director, officer: President and CEO	343 OYSTER POINT BLVD., SUITE 100, SOUTH SAN FRANCISCO CA 94080
Yu-waye Chu	officer: Chief Medical Officer	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Amy C. Peterson	officer: EVP, Chief Development Officer	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Alison L. Hannah	officer: Chief Medical Officer	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Alan Ashworth	director	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104